| Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ) |
|
|
| |
| • Company Description |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Number of Employees: 127 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $19.06 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 927,358 shares |
| Shares Outstanding: 62.78 (millions) |
| Market Capitalization: $1,196.49 (millions) |
| Beta: 0.37 |
| 52 Week High: $22.00 |
| 52 Week Low: $16.60 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-11.47% |
-14.13% |
| 12 Week |
5.25% |
-8.77% |
| Year To Date |
9.86% |
3.79% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo, Esq. - Chairman
Stephen Basso - Chief Financial Officer
Odysseas Kostas - Director
Jules Haimovitz - Director
|
|
Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 62.78
Most Recent Split Date: (:1)
Beta: 0.37
Market Capitalization: $1,196.49 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/25 |
|
|
|
| |
